Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Research

• Publication date

  2002-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12097293
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

  2001cited by this paper
• Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

  2001cited by this paper
• The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C*

  2001cited by this paper
• Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

  2001cited by this paper
• Von Hippel-Lindau disease: clinical and molecular perspectives.

  2001cited by this paper
• Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization

  2001cited by this paper
• Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

  2001cited by this paper
• TGFbeta and PTHrP control chondrocyte proliferation by activating cyclin D1 expression.

  2001cited by this paper
• Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.

  2001cited by this paper
• Fibronectin, integrins, and growth control

  2001cited by this paper
• Cyclin D1 polymorphism and increased risk of colorectal cancer at young age.

  2001cited by this paper
• Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle.

  2001cited by this paper
• The Von Hippel-Lindau Protein Interacts with Heteronuclear Ribonucleoprotein A2 and Regulates Its Expression*

  2001cited by this paper
• The Pezcoller lecture: cancer cell cycles revisited.

  2000cited by this paper
• Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage.

  2000cited by this paper
• Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling

  2000cited by this paper
• Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.

  2000cited by this paper
• Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

  2000cited by this paper
• CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.

  2000cited by this paper
• Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.

  2000cited by this paper
• Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein*

  2000cited by this paper
• Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

  2000cited by this paper
• Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury.

  2000cited by this paper
• Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer.

  2000cited by this paper
• Candidate genes for the hypoxic tumor phenotype.

  2000cited by this paper
• Cyclin‐D1 expression in human renal‐cell carcinoma

  1999cited by this paper
• The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

  1999influential reference
• Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.

  1999influential reference
• Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation

  1999cited by this paper
• Differential cyclin-dependent kinase expression and activation in human colon cancer.

  1999cited by this paper
• Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation.

  1999cited by this paper
• Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis

  1998cited by this paper
• Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck.

  1998cited by this paper
• Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2

  1998cited by this paper
• The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix.

  1998cited by this paper
• Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha.

  1998cited by this paper
• An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects.

  1998influential reference
• The VHL tumour-suppressor gene paradigm.

  1998cited by this paper
• Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.

  1998cited by this paper
• The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.

  1998cited by this paper
• Cyclin D1 expression in renal carcinomas and oncocytomas: an immunohistochemical study.

  1998cited by this paper
• Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.

  1998cited by this paper
• Transforming Growth Factor α Is a Target for the Von Hippel-Lindau Tumor Suppressor

  1998cited by this paper
• The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.

  1997cited by this paper
• Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.

  1996cited by this paper
• Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

  1996cited by this paper
• Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein*

  1996cited by this paper
• Type VIII collagen is a product of vascular smooth-muscle cells in development and disease.

  1996cited by this paper
• Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.

  1995cited by this paper
• Alternate splicing produces a novel cyclin D1 transcript.

  1995cited by this paper
• Tumour suppression by the human von Hippel-Lindau gene product

  1995cited by this paper
• Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect

  1995cited by this paper
• Interleukin-6 family of cytokines and gp130.

  1995cited by this paper
• Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.

  1994cited by this paper
• Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

  1994cited by this paper
• Mutations of the VHL tumour suppressor gene in renal carcinoma

  1994cited by this paper
• Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.

  1994cited by this paper
• Identification of the von Hippel-Lindau disease tumor suppressor gene.

  1993cited by this paper
• Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

  1992cited by this paper
• S phase of the cell cycle.

  1989cited by this paper
• A Wilcoxon-type test for trend.

  1985cited by this paper

• HIF sustain a transcriptional regulatory circuit of EPAS1 expression in renal clear cell carcinoma

  2026cites this paper
• Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer

  2025cites this paper
• Continuous-Time Quantum Walk on Biological Network

  2025cites this paper
• Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions

  2025cites this paper
• Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma

  2024cites this paper
• Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance

  2023cites this paper
• von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.

  2023cites this paper
• MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma

  2021cites this paper
• PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review)

  2021cites this paper
• Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.

  2020cites this paper
• A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB.

  2020cites this paper
• Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research

  2020cites this paper
• A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in clear cell renal cell carcinoma

  2019cites this paper
• Title Low VHL mRNA Expression is Associated with More Aggressive TumorFeatures of Papillary Thyroid Carcinoma

  2019cites this paper
• Adipose-derived exosomes deliver miR-23a/b to regulate tumor growth in hepatocellular cancer by targeting the VHL/HIF axis

  2019cites this paper
• Role of Hypoxia and Metabolism in the Development of Neointimal Hyperplasia in Arteriovenous Fistulas

  2019cites this paper
• HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species

  2019cites this paper
• Lysosomal acid lipase promotes cholesterol ester metabolism and drives clear cell renal cell carcinoma progression

  2018cites this paper
• von Hippel-Lindau disease: Diagnosis and factors influencing disease outcome.

  2018cites this paper
• Congenital and Inherited Anomalies of the Pancreas

  2018cites this paper
• Molecular-genetic diagnostics of von Hippel-Lindau syndrome (VHL) in Bulgaria: first complex mutation event in the VHL gene

  2018influential citation
• A Human Long Non-Coding RNA ALT1 Controls the Cell Cycle of Vascular Endothelial Cells Via ACE2 and Cyclin D1 Pathway

  2017cites this paper
• Hereditary Renal Cell Carcinoma

  2017cites this paper
• 8 Biological Aspects in Renal Cell Carcinoma

  2017cites this paper
• A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.

  2017cites this paper
• The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

  2017cites this paper
• Molecular characterisation of renal cell carcinoma and related disorders

  2016cites this paper
• Targeting HIF2 in Clear Cell Renal Cell Carcinoma.

  2016cites this paper
• Protein 4.1R Influences Myogenin Protein Stability and Skeletal Muscle Differentiation*

  2016cites this paper
• Correlation analysis of VHL and Jade-1 gene expression in human renal cell carcinoma

  2016cites this paper
• Protéine-kinases et cancer du rein : Découverte et validation d’une nouvelle combinaison d’inhibiteurs ciblant les protéine-kinases ATM et CK2

  2016cites this paper
• Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib

  2016cites this paper
• Correction: Identification of Cyclin D1 and Other Novel Targets for the von Hippel-Lindau Tumor Suppressor Gene by Expression Array Analysis and Investigation of Cyclin D1 Genotype as a Modifier in von Hippel-Lindau Disease.

  2015cites this paper
• Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies

  2015cites this paper
• VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications

  2015cites this paper
• Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma

  2014cites this paper
• First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response

  2014cites this paper
• DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells

  2014cites this paper
• Telomere shortening is associated with genetic anticipation in Chinese Von Hippel-Lindau disease families.

  2014cites this paper
• Transcriptome-Based Analysis of Kidney Gene Expression Changes Associated with Diabetes in OVE26 Mice, in the Presence and Absence of Losartan Treatment

  2014cites this paper
• VHL, the story of a tumour suppressor gene

  2014cites this paper
• An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma

  2014cites this paper
• TBX1 Mutation Identified by Exome Sequencing in a Japanese Family with 22q11.2 Deletion Syndrome-Like Craniofacial Features and Hypocalcemia

  2014cites this paper
• The role of inflammation in kidney cancer.

  2014cites this paper
• Genomics and epigenomics of renal cell carcinoma.

  2013cites this paper
• Clear Cell Carcinoma of Ovary and Uterus

  2013cites this paper
• A Genome-Wide Association Study of Renal Cell Carcinoma among African Americans

  2013cites this paper
• VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer

  2013cites this paper
• Von Hippel-Lindau protein and respiratory diseases

  2013cites this paper
• miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis

  2013cites this paper
• The VHL/HIF axis in clear cell renal carcinoma.

  2013cites this paper
• Molecular Biology of Kidney Cancer

  2012cites this paper
• Renal cancer: oxygen meets metabolism.

  2012cites this paper
• Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression

  2012cites this paper
• Genome-wide mapping of the hypoxic response

  2012cites this paper
• Molecular Biology of Clear Cell Renal Carcinoma

  2012cites this paper
• Biological Aspects in Renal Cell Carcinoma

  2012cites this paper
• Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL

  2011cites this paper
• Resistance to angiogenesis inhibitors in renal cell carcinoma.

  2011cites this paper
• New insights into the biology of renal cell carcinoma.

  2011cites this paper
• Insulin Receptor Substrate-2 (IRS-2): A Novel Hypoxia-Responsive Gene in Breast Cancer: A Dissertation

  2011cites this paper
• von Hippel–Lindau disease: A clinical and scientific review

  2011cites this paper
• Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1

  2011cites this paper
• Long-term outcomes, branch-specific expressivity, and disease-related mortality in von Hippel-Lindau type 2A

  2011cites this paper
• The Roles of Laparoscopic Liver Resection and Hypoxia Inducible Factor in the Pathophysiology of Liver cancer

  2011cites this paper
• Von Hippel-Lindau syndrome: molecular mechanisms of the disease

  2010cites this paper
• Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma.

  2010cites this paper
• The Role of Von-Hippel Lindau (VHL) protein in Regulating Cell Cycle Progression and the Expression of Fibronectin in the Human Placenta

  2010cites this paper
• Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics

  2010cites this paper
• Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD

  2010cites this paper
• The VHL tumor suppressor: master regulator of HIF.

  2009cites this paper
• Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease: Characterization by VHL/HIF Pathway Proteins Expression

  2009cites this paper
• CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma

  2009cites this paper
• Hypoxia regulated pathways inurological malignancies

  2009cites this paper
• The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies

  2009cites this paper
• Identification of novel VHL regulated genes by transcriptomic analysis of RCC10 renal carcinoma cells.

  2009cites this paper
• Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel‐Lindau transfectant cell line model

  2009cites this paper
• Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.

  2009cites this paper
• Treatment of kidney cancer

  2009cites this paper
• Targeting mTOR in renal cell carcinoma

  2009cites this paper
• Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma

  2009cites this paper
• Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes

  2009cites this paper
• Cyclin D1 A870G Polymorphism in Brazilian Colorectal Cancer Patients

  2008cites this paper
• Caveolin-1 and Flotillin-1 Differential Expression in Clinical Samples of Renal Cell Carcinoma

  2008cites this paper
• Hypoxia-inducible factor-2α regulates the expression of TRAIL receptor DR5 in renal cancer cells

  2008cites this paper
• Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

  2008cites this paper
• Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen

  2008cites this paper
• Germline Mutation in the von Hippel-Lindau Gene in Kuwait

  2008cites this paper
• Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice

  2008influential citation
• The VHL tumor suppressor and HIF: insights from genetic studies in mice

  2008cites this paper
• Caveolin-1 and Flotillin-1 Differential Expression in Clinical Samples of Renal Cell Carcinoma

  2008cites this paper
• Vertigo, disequilibrium, and dizziness

  2007cites this paper
• Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.

  2007cites this paper
• Characterization of a 3;6 translocation associated with renal cell carcinoma

  2007cites this paper
• THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN AND KIDNEY CANCER

  2007cites this paper
• VHL mutation analysis in patients with isolated central nervous system haemangioblastoma.

  2007cites this paper
• Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries

  2007cites this paper
• The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

  2007cites this paper
• The low-density lipoprotein receptor-related protein regulates cancer cell survival and metastasis development.

  2007cites this paper
• ErbB-2 Induces Bilateral Adrenal Pheochromocytoma Formation in Mice

  2007cites this paper